Europe Precision Oncology Market Size & Outlook, 2024-2030
Europe precision oncology market, 2018-2030 (US$M)
Related Markets
Europe precision oncology market highlights
- The Europe precision oncology market generated a revenue of USD 30,787.3 million in 2024.
- The market is expected to grow at a CAGR of 9.4% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 30,787.3 million |
| Market revenue in 2030 | USD 52,610.0 million |
| Growth rate | 9.4% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.6% of the global precision oncology market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 50,287.5 million by 2030.
Therapeutics was the largest segment with a revenue share of 77.83% in 2024. Horizon Databook has segmented the Europe precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in Europe is likely to emerge as a lucrative region due to the growing focus on innovative therapies for rare cancers through strategic collaborations and advancements in radioligand treatments. For instance, in September 2024, Sanofi announced a licensing agreement with RadioMedix and Orano Med highlighting the development of AlphaMedix (212Pb-DOTAMTATE), a targeted alpha therapy for somatostatin receptor-expressing neuroendocrine tumors.
This next-generation radioligand medicine leverages lead-212 to deliver precise, targeted cancer treatment, addressing the unmet needs of patients with rare and difficult-to-treat cancers. Such initiatives are advancing precision medicine in Europe, driving growth through innovative solutions tailored to specific cancer subtypes.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe precision oncology market size, by country, 2018-2030 (US$M)
Europe Precision Oncology Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
